Table 4 Concordance of Antibody Identification Among Designs when Applied to Example Data. Results of implementing the designs on resampled example data, comparing the case control design and two-phase group testing design with group sizes 5, 10, and 20. Note that the standard group testing design will identify the same significant antibodies as the case control design, so results are not explicitly listed for simplicity
Case Control Design | Â | Number of Antibodies Significant | |
642 | |||
Two-Phase Group Testing Design | Number Significant of Significant in CC | Number Not Significant of Significant in CC | |
Group Size 5 | 641 (99.84%) | 1 (0.16%) | |
Group Size 10 | 635 (98.91%) | 7 (1.09%) | |
Group Size 20 | 621 (96.73%) | 21 (3.27%) | |
Case Control Design | Â | Number of Antibodies Not Significant | |
2,413 | |||
Two-Phase Group Testing Design | Number Significant of Not Significant in CC | Number Not Significant of Not Significant in CC | |
Group Size 5 | 13 (0.54%) | 2,400 (99.46%) | |
Group Size 10 | 14 (0.58%) | 2,399 (99.42%) | |
Group Size 20 | 12 (0.50%) | 2,401 (99.50%) | |